NCT07015021View on ClinicalTrials.gov

The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM Patients

NANot yet recruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Multiple MyelomaCarfilzomibDaratumumabPomalidomide
Interventions
DRUG

Daratumumab

Daratumumab: 16mg/Kg, IV or 1800mg Sc; C1-2 d1,8,15,22; C3-6 d1,15; C7-12 d1

DRUG

Cafizomide

Cafizomide: 20mg/m2; C1-8 d1,2,8,9,15,16； C9-12 d1,2,15,16；After tolerance to 20mg/m2, the dose of C1D1 and C1D2 can be adjusted to 27g/m2.

DRUG

Pomalidomide

Pomalidomide: 4mg, PO,d1-21

DRUG

Dexamethasone

Dexamethasone: 20mg, po,d1, 2,8,9,15,16,22,23.

All Listed Sponsors
lead

The First Affiliated Hospital of Soochow University

OTHER

NCT07015021 - The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM Patients | Biotech Hunter | Biotech Hunter